‘Fitness, fresh air and forward thinking’: Cape to Cape for Cannabis Delivers New Insights
The Cape to Cape cannabis education event enhances clinician knowledge in medical cannabis. This professional development supports evidence-based prescribing and safe use. Clinicians benefit from updated cannabis pharmacology and regulatory insights.
DOJ Reschedules Medical Marijuana: What It Means for Insurance Coverage
The DOJ's rescheduling of medical marijuana has significant medical marijuana insurance coverage implications. This change may increase insurance reimbursement options and reduce patient costs. Clinicians can now better guide patients on accessing…
Will the Medical Cannabis Market Grow as More Countries Approve
✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchIndustry Why This Matters As more countries approve medical cannabis based on emerging clinical evidence,…
What Doctors Want You to Know About Cannabis and Health – The New York Times
✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchSafetyAgingPainAnxiety Why This Matters Clinicians need current evidence on cannabis safety and efficacy in…
Medical Marijuana Reclassification: New Research Opportunities – Observer Voice
Cannabis reclassification medical research is opening new doors for rigorous clinical studies on therapeutic efficacy and safety. This shift reduces federal barriers, enabling better evidence generation. Clinicians can now anticipate improved guidelines…
The Future of Clinical Research: Why Innovation Must Be Matched with Accountability
✦ New CED Clinical Relevance #52 Clinical Context Background information relevant to the evolving cannabis medicine landscape. ResearchSafetyPolicyIndustry Clinical Summary # Clinical Summary The accelerating development of cannabinoid-based…
What we know—and what we don’t—about marijuana’s health effects | Scientific American
✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchSafetyTHCCBDMental Health Why This Matters Clinicians need current evidence about cannabis’s health…
France’s Medical Cannabis Trial: 3% Serious Adverse Events in 3,164 Patients Over Three Years
The medical cannabis safety adverse drug reactions study in France tracked 3,164 patients over three years. It found 3% experienced serious adverse drug reactions, mainly neurological, gastrointestinal, and psychiatric. This observational study provides…
Should marijuana access be expanded? On April 23, 2026, the Trump administration … – Facebook
✦ New CED Clinical Relevance #55 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyResearchMedical MarijuanaMental Health Clinical Summary The Trump administration’s April 2026 policy…
The Biggest Things About Schedule III You Haven’t Thought Of | Cannabis Business Times
✦ New CED Clinical Relevance #65 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchIndustry Clinical Summary # Clinical Summary The potential rescheduling of cannabis from Schedule I to…